Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal study of Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume. “Achieving positive topline results in our mid-face study is an important milestone for Evolus as we expand beyond Jeuveau® with the Evolysse™ line,” said David